CHEETA (Chasing Expedited and Equitable Treatment Access for Children) is committed to transforming the landscape of pediatric tuberculosis (TB) treatment by accelerating the development, evaluation, and access to safer, more effective, and child-friendly TB medications. Recognizing the urgent need to address the disproportionate burden of TB among children—especially those under five and those with drug-resistant TB—CHEETA aims to eliminate the delays and inefficiencies that have historically hindered pediatric drug development. Through a groundbreaking platform trial model, CHEETA will implement harmonized, efficient, and scientifically rigorous studies that prioritize early inclusion of children, leverage pharmacometric modeling, and ensure acceptability and safety across all age groups.

By fostering strong partnerships with pharmaceutical innovators, global health stakeholders, and affected communities, CHEETA will build a sustainable research infrastructure that supports ongoing and future pediatric TB drug evaluations. The initiative will streamline regulatory processes, expand global trial site capacity, and ensure that children in high TB burden settings are not left behind. Through this collaborative and adaptive approach, CHEETA seeks to deliver on its promise: faster, equitable access to optimized TB treatments for all children, everywhere.